No

Vaccine

Selective active immunization against rubella; vaccination is routinely recommended for persons from 12 months of age to puberty. All adults, both male and female, lacking documentation of live vaccine on or after first birthday, or laboratory evidence of immunity (particularly women of childbearing age and young adults who work in or congregate in hospitals, colleges, and on military bases) should be vaccinated. Susceptible travelers should be vaccinated.

C

Women who are pregnant when vaccinated or who become pregnant within 3 months of vaccination should be counseled on the theoretical risks to the fetus. The risk of rubella-associated malformations in these women is so small as to be negligible. MMR is the vaccine of choice if recipients are likely to be susceptible to measles or mumps as well as to rubella.

Pregnancy, immunocompromised persons, history of anaphylactic reaction following receipt of neomycin; do not administer with other live vaccines

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Dermatologic: Local tenderness and erythema

Neuromuscular & skeletal: Arthralgia

1% to 10%:

Central nervous system: Malaise, moderate fever, headache

Dermatologic: Rash, urticaria

Gastrointestinal: Sore throat

Miscellaneous: Lymphadenopathy

<1%: High fever (>103°F), encephalitis, polyneuropathy, erythema multiforme, optic neuritis, hypersensitivity, allergic reactions to the vaccine

Whole blood, interferon immune globulin, radiation therapy, and immunosuppressive drugs (eg, corticosteroids) may result in insufficient response to immunization; may temporarily depress tuberculin skin test sensitivity and reduce the seroconversion. DTP, OPV, MMR, Hib, and hepatitis B may be given concurrently; other virus vaccine administration should be separated by greater than or equal to 1 month from measles.

Refrigerate, discard reconstituted vaccine after 8 hours; store at 2°C to 8°C (36°F to 46°F); ship vaccine at 10°C; may use dry ice, protect from light

Rubella vaccine is a live attenuated vaccine that contains the Wistar Institute RA 27/3 strain, which is adapted to and propagated in human diploid cell culture. Promotes active immunity by inducing rubella hemagglutination-inhibiting antibodies.

Onset of effect: Antibodies to the vaccine are detectable within 2-4 weeks following immunization

Children greater than or equal to 12 months and Adults: S.C.: 0.5 mL in outer aspect of upper arm; children vaccinated before 12 months of age should be revaccinated

S.C. injection only

May depress tuberculin skin test sensitivity

No information available to require special precautions

No effects or complications reported

Patient may experience burning or stinging at the injection site; joint pain usually occurs 1-10 weeks after vaccination and persists 1-3 days

Reconstituted vaccine should be used within 8 hours; S.C. injection only

Injection, single dose: 1000 TCID_5O (Wistar RA 27/3 Strain)

Gardner P and Schaffner W, "Immunization of Adults," N Engl J Med, 1993, 328(17):1252-8.